@article{803ece1fb9ed4b8fbed6178df4768a0a,
title = "New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research",
abstract = "The International Society for Stem Cell Research (ISSCR) task force that developed new Guidelines for the Clinical Translation of Stem Cells discusses core principles that should guide the responsible transition of basic stem cell research into appropriate clinical applications.",
author = "Insoo Hyun and Olle Lindvall and Lars {\"A}hrlund-Richter and Elena Cattaneo and Marina Cavazzana-Calvo and Giulio Cossu and {De Luca}, Michele and Fox, {Ira J.} and Claude Gerstle and Goldstein, {Robert A.} and G{\"o}ran Hermer{\'e}n and High, {Katherine A.} and Kim, {Hyun Ok} and Lee, {Hin Peng} and Ephrat Levy-Lahad and Lingsong Li and Bernard Lo and Marshak, {Daniel R.} and Angela McNab and Megan Munsie and Hiromitsu Nakauchi and Mahendra Rao and Rooke, {Heather M.} and Valles, {Carlos Simon} and Alok Srivastava and Jeremy Sugarman and Taylor, {Patrick L.} and Anna Veiga and Wong, {Adrianne L.} and Laurie Zoloth and Daley, {George Q.}",
note = "Funding Information: The ISSCR Guidelines for the Clinical Translation of Stem Cells were created by a multinational, multidisciplinary group of researchers, clinicians, ethicists, and regulatory officials from 13 countries. The ISSCR wishes to acknowledge the financial support of the EUROCORES Programme EuroSTELLS, a European Science Foundation (ESF) initiative, supported by the European Commission, Sixth Framework Programme, under contract number ERAS-CT-2003-98409. Research funding is provided by participating national organizations. EuroSTELLS is managed by the European Medical Research Councils (EMRC) at the ESF. The ISSCR also thanks the Alzheimer's Research Foundation, The Ellison Medical Foundation, and the Juvenile Diabetes Research Foundation for their generous financial support of the task force. The task force wishes to acknowledge helpful consultation from representatives of the U.S. Food and Drug Administration. D.R.M. is an employee, corporate officer, and shareholder of PerkinElmer Inc., which sells instruments, reagents, software, and services to the pharmaceutical, biotechnology, and medical device industries. PerkinElmer Inc. also has a business that provides services for umbilical cord blood banking, neonatal screening, and prenatal screening. M.R. is an employee of Invitrogen Inc., which provides goods and services to the research industry, including the cell therapy industry. ",
year = "2008",
month = dec,
day = "4",
doi = "10.1016/j.stem.2008.11.009",
language = "English (US)",
volume = "3",
pages = "607--609",
journal = "Cell stem cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "6",
}